SPECT/CT in Endocrine and Neuroendocrine Tumors
Primary Purpose
Endocrine and Neuroendocrine Tumors
Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
SPECT/CT
Sponsored by
About this trial
This is an interventional diagnostic trial for Endocrine and Neuroendocrine Tumors
Eligibility Criteria
Inclusion Criteria: Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors. Patient signed informed consent Exclusion Criteria: The study will not be performed in pregnant or lactating women. Patient will not be able or willing to tolerate the scan until its completion.
Sites / Locations
- Rambam Medical Center
Outcomes
Primary Outcome Measures
The impact of imaging modality on patient management
Secondary Outcome Measures
The impact of imaging modality on patient management
Full Information
NCT ID
NCT00230139
First Posted
September 29, 2005
Last Updated
October 11, 2008
Sponsor
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT00230139
Brief Title
SPECT/CT in Endocrine and Neuroendocrine Tumors
Official Title
The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
January 2002 (undefined)
Primary Completion Date
January 2004 (Actual)
Study Completion Date
January 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Rambam Health Care Campus
4. Oversight
5. Study Description
Brief Summary
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:
Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.
It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.
Detailed Description
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:
Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.
It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endocrine and Neuroendocrine Tumors
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
SPECT/CT
Primary Outcome Measure Information:
Title
The impact of imaging modality on patient management
Secondary Outcome Measure Information:
Title
The impact of imaging modality on patient management
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
Patient signed informed consent
Exclusion Criteria:
The study will not be performed in pregnant or lactating women.
Patient will not be able or willing to tolerate the scan until its completion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zohar Keidar, MD,PhD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Medical Center
City
Haifa
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
SPECT/CT in Endocrine and Neuroendocrine Tumors
We'll reach out to this number within 24 hrs